Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes

Patients with type 2 diabetes are at high risk of developing renal and cardiovascular complications. Sodium–glucose cotransporter (SGLT2) inhibitors have garnered interest due to their glucose-independent cardiorenal protective effects, as reported in trials including participants without diabetes, such Dapagliflozin And Prevention Adverse outcomes Chronic Kidney Disease (DAPA-CKD) (1,2). These demonstrated that SGLT2 reduce disease (CVD) risk, especially hospitalization for heart failure Despite these clinical benefits, the underlying physiological mechanisms incompletely understood, particularly patients chronic kidney (CKD). Accordingly, this analysis examined impact treatment an inhibitor, ertugliflozin, on markers plasma volume contraction myocardial strain moderate CKD. We performed a post hoc exploratory subset 231 from eValuation ERTugliflozin efficacy Safety (VERTIS) RENAL trial (clinical reg. no. NCT01986855, ClinicalTrials.gov) stage 3 CKD (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2) who were randomized inhibitor therapy ertugliflozin (5 mg or 15 daily; pooled herein) placebo (3). Clinical biomarker measurements obtained baseline 26 weeks 52 postrandomization. Biomarkers quantified Luminex xMAP (cardiac troponin, renin, N-terminal pro B-type natriuretic peptide [NT-proBNP]) ELISA (atrial [ANP], human erythropoietin [EPO], ACE, ACE2). Aldosterone was by DiaSorin LIAISON XL Analyzer based competitive chemiluminescent immunoassay. Differences longitudinal changes biomarkers among receiving either …